Compare MEDP & NLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEDP | NLY |
|---|---|---|
| Founded | 1992 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 15.3B |
| IPO Year | 2016 | 1997 |
| Metric | MEDP | NLY |
|---|---|---|
| Price | $557.87 | $22.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $465.18 | $21.63 |
| AVG Volume (30 Days) | 265.4K | ★ 6.7M |
| Earning Date | 10-22-2025 | 01-28-2026 |
| Dividend Yield | N/A | ★ 12.63% |
| EPS Growth | ★ 25.36 | N/A |
| EPS | ★ 14.32 | 2.19 |
| Revenue | ★ $2,358,373,000.00 | $1,748,174,000.00 |
| Revenue This Year | $21.48 | $358.71 |
| Revenue Next Year | $11.90 | $8.02 |
| P/E Ratio | $38.96 | ★ $10.10 |
| Revenue Growth | 13.88 | ★ 275.23 |
| 52 Week Low | $250.05 | $16.60 |
| 52 Week High | $626.26 | $22.98 |
| Indicator | MEDP | NLY |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 50.51 |
| Support Level | $530.96 | $22.66 |
| Resistance Level | $569.00 | $22.52 |
| Average True Range (ATR) | 16.60 | 0.30 |
| MACD | -4.63 | -0.08 |
| Stochastic Oscillator | 28.24 | 33.06 |
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Annaly Capital Management Inc is an American mortgage real estate investment trust. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The company's reportable operating segments are; the Agency segment, which invests in Agency mortgage-backed securities collateralized by residential mortgages; the Residential Credit segment, which invests in non-Agency residential whole loans and securitized products within the residential and commercial markets; the Mortgage Servicing Rights segment; and Corporate & Other. Maximum revenue for the company is generated from its Agency segment.